CAR T-Cell Therapy, an immunotherapy, is a novel therapy that  programs a patient’s immune system  to recognize and fight cancer. The immune system is responsible for ridding the body of abnormal cells that are foreign (like cancer) or infected. T-lymphocytes (T-Cells) are a type of cell responsible for killing abnormal cells. During the CAR T-Cell treatment process, T-Cells are drawn from a patient's blood and genetically modified to recognize the patient’s cancer cells when reinfused.

Here’s how it works:

  1. First, a patient’s white blood cells are collected through a process called apheresis.
  2. Then, the T-Cells are isolated from other blood cells.
  3. T-Cells are then modified in a special facility to program them to recognize the cancer cells, what can be thought of as “fighter” T-Cells.
  4. Lastly, the new “fighter” T-Cells are reinfused into the patient to target and kill  the cancer.

CAR T-Cell Therapy

Sarah Cannon Blood Cancer Network located in Austin, Dallas, Denver, Kansas City, Nashville and San Antonio in the United States. In the United Kingdom, located in London and Manchester.

Sarah Cannon Blood Cancer Network programs across the United States offer both research and FDA-approved CAR T-Cell Therapy options and have been actively involved in CAR T-Cell clinical trials for years. In fact, Sarah Cannon was one of the first non-university research centers to offer this therapy, continuing our mission to treat patients with promising new agents close to home.

CAR T-Cell Therapy Clinical Trials:

Learn more about CAR T-Cell therapy, a type of immunotherapy, from Dr. David Spigel, MD, Chief Scientific Officer at Sarah Cannon Research Institute on Fox News.